Accelerating Detection & Characterization of Biomolecules with Surface Plasmon Resonance to Make Key Immunological Advancement


  • Victor Chanda, Ph.D., PMP, Field Application Scientist
  • Mike Piazza, Ph.D., Systems Integration Manager

Characterization of key target-receptor interactions is vital to therapeutic discovery for immune-mediated diseases, yet current technologies have both limited applications and challenges with instrumentation complexity. Surface plasmon resonance has been increasingly adopted by immunologists as the gold-standard for biomolecular characterization, providing an information-rich and flexible technique for analyzing protein-receptor interactions, viral protein-host protein interactions, and other therapeutic applications that advances our understanding of these diseases. Join us as we discuss how our unique localized SPR technology is empowering infectious disease researchers in accelerating the development of novel therapeutics and diagnostics.

PBMC Single-Cell Transcriptomics Reveals Immunoregulation of COVID-19 During Disease Progress and Corticosteroid Treatment


  • Margaret Nakamoto, Ph.D., Manager, Single-Cell Multioic Analyses
  • Hyun-Woo, Ph.D., CEO einocle Inc.

Microfluidic Gentle Cell Sorting for Immunology Applications


  • Lindsey Wolf, Product Manager

The WOLF Cell Sorter from NanoCellect Biomedical was designed to provide an affordable microfluidic benchtop solution to sort cells easily and gently using sterile microfluidic cartridges. NanoCellect is launching the WOLF G2 cell sorter, a 2-laser system with up to 9 fluorescent channels to enable a broader range of applications. During this workshop we will review several case studies highlighting how the WOLF can use intuitive multi-color sorting strategy to isolate sensitive cells such as neutrophils and improve sample preparation of peripheral blood mononuclear cells for 10x Genomics single-cell RNA-Seq.

Investigating COVID-19 Immune Response with the Cytek® Aurora


  • Maria Jaimes, Vice President of Applications
  • Geoff Kraker, Global Data Analyst

Inside the COVID-SeroIndex™ Assay Design and Performance


  • Greta Wagner, Ph.D., Senior Director, ELISAs
  • Mandy Kubik, Manager, Assay Development
  • Anthony Person, Ph.D., Senior Director, Proteins

Understanding immune responses to COVID-19 and vaccines to SARS-CoV-2 is essential when profiling disease progression or vaccine efficacy. Bio-Techne and our partner, Kantaro Biosciences – a Mount Sinai Venture, have developed the COVID-SeroIndex™, a quantitative ELISA kit that enables an objective measurement of SARS-CoV-2 IgG antibodies. Join us as our panel of experts discuss procedure and performance that leads to the fast acquisition of the accurate and proven results required in today’s market.

Enabling New Insights in Viral Immunology through Ultra-Sensitive Biomarker Analysis


  • Andrew Ball, Ph.D.

In this workshop, Andrew Ball Ph.D., VP of Assay R&D at Quanterix, will describe the latest advances in the development of ultra-sensitive Simoa immunoassays and their application towards enabling insights into viral immunology, with a particular focus on COVID-19. This workshop will include data on SARS-CoV-2 viral antigen detection in multiple biofluids, quantitative assessment of the innate and adaptive immune responses to SARS-CoV-2, and multiparametric longitudinal proteomic analysis of cytokine and chemokine responses in individuals infected with SARS-CoV-2.

A Single Regulatory T Cell Pool Patrols the Tissues


  • Oliver Burton, Ph.D.
  • Mike Blundell, Ph.D.

Recent studies have identified Foxp3+ regulatory T cells (Tregs) in several non-lymphoid tissues. Using high parameter flow cytometry and StarBright Dyes, we profiled and quantified murine Tregs throughout the body and revealed shared phenotypes in this tiny population of cells. We find that Tregs isolated from non-lymphoid tissues display little or no homing preference for their tissue of origin, and exhibit TCR activation in their new locations. We conclude that a single pool of broadly self-reactive activated Tregs patrols non-lymphoid tissues.